Interestingly, the efficacy of ruxolitinib was observed not only in three samples with JAK1 or JAK3 mutation, but also in two ETP-ALL samples without JAK1, JAK3, or IL7R mutation [10]. This evidence concerns the gene JAK1 and acute lymphoblastic leukemia.